Milestone Pharmaceuticals, Inc. is a biopharmaceutical company dedicated to developing innovative treatments for cardiovascular conditions, specifically focusing on acute episodes of paroxysmal supraventricular tachycardia (PSVT) and atrial fibrillation with rapid ventricular rate (AFib-RVR). The company has developed Etripamil, a novel nasal spray calcium channel blocker, designed for at-home treatment, providing an alternative to emergency department or hospital visits. Milestone Pharmaceuticals aims to offer cardiac peace of mind through targeted therapy solutions that address episodic cardiovascular conditions outside of traditional healthcare settings.
October 22
Manage pharmaceutical development for nasal and sublingual drug products at Milestone Pharmaceuticals.